UK Court Ruling Ends Novartis/Bayer Crusade Against Avastin In AMD
Off-Label Use Does Not Undermine Licensing System
Executive Summary
AMD patients in the UK can legitimately be given compounded bevacizumab (Roche’s Avastin) after the appeals court said NHS trusts could offer a drug off-label for economic reasons where there were no safety or efficacy concerns.
You may also be interested in...
Outlook To Make Its Case For Ophthalmic Bevacizumab At High-Stakes EMA Meeting
Outlook Therapeutics is hoping to secure EU marketing approval for the first ophthalmic formulation of bevacizumab.
Ophthalmic Bevacizumab & CRISPR-Based Gene Therapy Among Latest EU Filings
Investigational drugs from Outlook Therapeutics and Vertex/CRISPR could become first-of-their-kind products if they win marketing approval.
Ophthalmic Bevacizumab Sponsor Not Giving Up On EMA Rejection
The European Medicines Agency has been asked to re-examine its rejection of the EU marketing application for Ipique, which, if approved, could become the first drug containing bevacizumab to be authorized for use in neovascular (wet) macular degeneration.